Alumis (NASDAQ:ALMS) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Alumis (NASDAQ:ALMS) in a research note issued to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a $15.00 price objective on the stock. HC Wainwright also issued estimates for Alumis’ Q1 2025 earnings at ($1.29) EPS, Q1 2025 earnings at ($1.07) EPS, Q2 2025 earnings at ($0.81) EPS, Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at ($3.39) EPS and FY2025 earnings at ($4.26) EPS.

ALMS has been the topic of several other reports. Oppenheimer started coverage on shares of Alumis in a research note on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research note on Thursday, March 20th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Alumis presently has an average rating of “Buy” and an average price target of $26.00.

Alumis Price Performance

NASDAQ ALMS opened at $5.64 on Wednesday. The business has a fifty day moving average price of $5.39 and a 200 day moving average price of $8.34. Alumis has a one year low of $3.18 and a one year high of $13.53.

Hedge Funds Weigh In On Alumis

A number of hedge funds have recently modified their holdings of ALMS. BNP Paribas Financial Markets purchased a new position in shares of Alumis during the 3rd quarter worth approximately $27,000. MetLife Investment Management LLC acquired a new position in Alumis during the 3rd quarter worth about $89,000. Wells Fargo & Company MN boosted its holdings in Alumis by 77.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock valued at $69,000 after acquiring an additional 3,823 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in shares of Alumis in the fourth quarter valued at approximately $79,000. Finally, Marshall Wace LLP purchased a new stake in Alumis during the 4th quarter worth approximately $108,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.